Press Releases Items Per Page 102550 Year None202320222021202020192018201720162015201420132012201120102007 08.07.19 Syndax Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Clinical and Business Update 08.05.19 Syndax to Participate in the BTIG Biotechnology Conference 07.31.19 Syndax to Announce Second Quarter 2019 Financial Results and Host Conference Call and Webcast on August 7, 2019 07.10.19 Syndax Pharmaceuticals Announces FDA Clearance of IND Application for Targeted Menin Inhibitor SNDX-5613 for Relapsed/Refractory Acute Leukemias 06.13.19 Syndax to Present at the JMP Securities Life Sciences Conference 05.14.19 Syndax to Present at the UBS Global Healthcare Conference 05.06.19 Syndax Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Clinical and Business Update 04.29.19 Syndax to Announce First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 6, 2019 04.01.19 Syndax Pharmaceuticals Presents Updated Phase 2 Data from ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab) at the American Association for Cancer Research 2019 Annual Meeting 03.27.19 Syndax Announces $26.2 Million Offering of Common Stock and Warrants 03.07.19 Syndax Pharmaceuticals Reports Fourth Quarter 2018 Financial Results and Provides Clinical and Business Update 03.06.19 Syndax to Present at the Cowen 39th Annual Health Care Conference Pagination First page « first Previous page ‹ previous … Page 5 Page 6 Page 7 Page 8 Current page 9 Page 10 Page 11 Page 12 Page 13 … Next page next › Last page last »
08.07.19 Syndax Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Clinical and Business Update
07.31.19 Syndax to Announce Second Quarter 2019 Financial Results and Host Conference Call and Webcast on August 7, 2019
07.10.19 Syndax Pharmaceuticals Announces FDA Clearance of IND Application for Targeted Menin Inhibitor SNDX-5613 for Relapsed/Refractory Acute Leukemias
05.06.19 Syndax Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Clinical and Business Update
04.29.19 Syndax to Announce First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 6, 2019
04.01.19 Syndax Pharmaceuticals Presents Updated Phase 2 Data from ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab) at the American Association for Cancer Research 2019 Annual Meeting
03.07.19 Syndax Pharmaceuticals Reports Fourth Quarter 2018 Financial Results and Provides Clinical and Business Update
